| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human OAT1/SLC22A6 recombinant protein (Position: R286-L563) was used as the immunogen for the OAT1 antibody. |
| Isotype | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
OAT1 Antibody / Organic anion transporter 1 / SLC22A6 is a anti-OAT1 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as ELISA, Flow cytometry (FACS), Western blot (WB) with listed reactivity in Human.
Key elements and design rationale
- Target: OAT1
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): ELISA, FACS, WB
Biological background
OAT1 is encoded by the SLC22A6 gene located on human chromosome 11q12.3. The protein is approximately 563 amino acids long and belongs to the solute carrier 22 family. OAT1 is expressed predominantly in the basolateral membrane of renal proximal tubule cells, where it mediates the uptake of organic anions from the bloodstream into tubular cells, enabling their secretion into urine via apical transporters.
The OAT1 antibody detects a 60 kilodalton band by western blot and shows basolateral membrane staining in kidney tissue sections. OAT1 transports metabolites such as urate, prostaglandins, and p-aminohippurate, as well as drugs including antivirals, diuretics, and antibiotics. Its activity depends on the transmembrane exchange of alpha-ketoglutarate, coupling organic anion uptake to cellular metabolism.
Because OAT1 handles many pharmaceuticals, it is a major determinant of drug pharmacokinetics and toxicity. Inhibition or saturation of OAT1 can lead to altered drug clearance and nephrotoxicity. Genetic polymorphisms in OAT1 affect drug response variability and susceptibility to renal injury. Beyond renal physiology, OAT1 contributes to organic acid homeostasis in the brain and choroid plexus.
By regulating solute movement between blood and urine, OAT1 maintains chemical balance and metabolic detoxification.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
